Results 1 to 10 of about 40,684 (247)

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland [PDF]

, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but not
Gerber, B., Anne Angelillo-Scherrer, Pierre Fontana, Lorenzo A. Alberio, Angelillo-Scherrer, A., Angelillo, Anne, Alberio, Lorenzo A, Alberio, L.A., Bernhard Gerber, Gerber, Bernhard, Studt, J.D., Casini, Alessandro, Studt, Jan-Dirk, Alessandro Casini, Jan-Dirk Studt, Fontana, P., Fontana, Pierre, Casini, A., Angelillo-Scherrer, Anne   +18 more
core   +1 more source

Anticoagulation by factor Xa inhibitors [PDF]

Journal of Thrombosis and Haemostasis, 2010
Therapeutic agents that regulate blood coagulation are critical to the management of thrombotic disorders, with the selective targeting of factor (F) Xa emerging as a promising approach.To assess anticoagulant strategies targeting FXa.A deterministic computational model of tissue factor (Tf)-initiated thrombin generation and two empirical experimental ...
T, Orfeo, S, Butenas, K E, Brummel-Ziedins, M, Gissel, K G, Mann   +4 more
openaire   +2 more sources

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ, Bounameaux, H, A. John Camm, Henri Bounameaux   +3 more
core   +1 more source

Factor Xa or thrombin: is factor Xa a better target? [PDF]

Journal of Thrombosis and Haemostasis, 2007
Existing vitamin K antagonists (VKAs) have drawbacks that limit their effectiveness, safety, and overall frequency of use. Oral anticoagulants in development with targeted action against individual coagulation factors, specifically direct factor (F) Xa and IIa inhibitors, appear to have pharmacokinetic and pharmacodynamic properties that overcome the ...
openaire   +2 more sources

Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells [PDF]

, 1998
Proinflammatory effects induced by the serine protease factor Xa were investigated in HUVEC. Exposure of cells to factor Xa (5-80 nM) concentration dependently stimulated the production of IL-6, IL-8, and monocyte chemotactic protein-1 (MCP-1) and the ...
Buurman, W.A., Senden, N.H.M., van 't Veer, C., Hemker, H.C., Heemskerk, J.W.M., Wagenvoord, R.J., Jeunhomme, G.M.A.A.   +6 more
core   +2 more sources

Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity [PDF]

, 1998
Tissue factor : factor VIIa induced activation of blood coagulation is inhibited by the complex between factor Xa and tissue factor pathway inhibitor (factor Xa : TFPI).
Hemker, H. Coenraad, Li, Anguo, Willems, George M., Theo Lindhout, Wun, Tze-Chein, Irene Salemink, Salemink, Irene, Anguo Li, Tze-Chein Wun, George Willems, Franssen, Jo, Coenraad Hemker, Lindhout, Theo, Jo Franssen   +13 more
core   +1 more source

Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X [PDF]

, 2010
Human adenoviruses from multiple species bind to coagulation factor X (FX), yet the importance of this interaction in adenovirus dissemination is unknown.
Angela C Bradshaw, Duffy, Margaret R., Andrew H. Baker, Lynda Coughlan, Coughlan Lynda, Baker Andrew H., van Rooijen, Nico, van Rooijen, N., Nicklin, Stuart A., Margaret R Duffy, Parker, A.L., Kahari, V.M., Alan L Parker, Kähäri Veli-Matti, Stuart A Nicklin, Nico van Rooijen, Andrew H Baker, Coughlan, L., Nicklin Stuart A., Coughlan, Lynda, Kahari, Veli-Matti, Duffy, M.R., Parker Alan L., Bradshaw Angela C., Parker, Alan L., Duffy Margaret R., Bradshaw, Angela C., Bradshaw, A.C., Rooijen, N. van, Veli-Matti Kähäri, Angela C. Bradshaw, Alan L. Parker, Margaret R. Duffy, Stuart A. Nicklin, Baker, Andrew H., Baker, A.H., Nicklin, S.A., van Rooijen Nico   +37 more
core   +1 more source

Factor Va-factor Xa interaction:Effects of phospholipid vesicles of varying composition [PDF]

, 1982
The interaction between factor Xa and factor Va was investigated both in solution and in the presence of phospholipid vesicles with varying contents of phosphatidylserine.
Hemker, H. Coenraad, van de Waart, Piet, Lindhout, Theo, Rosing, Jan, Govers-Riemslag, Jose W.P.   +4 more
core   +1 more source

The role of factor Xa inhibitors in venous thromboembolism treatment

, 2015
Katherine P Cabral,1 Jack E Ansell2 1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA Abstract: Three factor Xa inhibitors have been studied
Ansell, J. E., Cabral KP, Cabral, K. P., Ansell JE   +3 more
core   +1 more source

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

, 2017
The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to the clinical use of the direct oral inhibitors of blood coagulation factor Xa.
Verhoef, Daniël, Daan P. Geerke, C. Ruben Vosmeer, Vosmeer, C Ruben, Geerke, Daan P; id_orcid, Daniël Verhoef, Geerke, Daan P, Koen M. Visscher, Pieter H. Reitsma, Reitsma, Pieter H, Visscher, Koen M, Cheung, Ka Lei, Bos, Mettine H A, Ka Lei Cheung, Mettine H. A. Bos   +14 more
core   +1 more source